Cargando…
Tissue factor activity on microvesicles from cancer patients
PURPOSE: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985086/ https://www.ncbi.nlm.nih.gov/pubmed/31734835 http://dx.doi.org/10.1007/s00432-019-03073-0 |
_version_ | 1783491745451868160 |
---|---|
author | Ender, Fanny Freund, Annika Quecke, Tabea Steidel, Corinna Zamzow, Piet von Bubnoff, Nikolas Gieseler, Frank |
author_facet | Ender, Fanny Freund, Annika Quecke, Tabea Steidel, Corinna Zamzow, Piet von Bubnoff, Nikolas Gieseler, Frank |
author_sort | Ender, Fanny |
collection | PubMed |
description | PURPOSE: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown high expression variability. As a contribution to this discussion, we present a study investigating plasma samples from patients with various progressive tumors at high risk for VTE. METHODS: Based on our previous study uncovering microvesicles (MVs), the larger ectosome-like extracellular vesicles (EV), as the major source of TF activity in EV preparations, we now determined TF activity on enriched MVs isolated from plasma of cancer patients and compared it with that on MVs from healthy individuals. RESULTS: We found considerably higher amounts of MVs as well as higher levels of MV-bound TF activities in the plasma of cancer patients. We also show that preparations from plasma of cancer patients have the potency to induce ERK phosphorylation in a human tumor cell line through proteinase-activated receptor two (PAR2) activation. CONCLUSION: We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE. GRAPHIC ABSTRACT: [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03073-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6985086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-69850862020-02-07 Tissue factor activity on microvesicles from cancer patients Ender, Fanny Freund, Annika Quecke, Tabea Steidel, Corinna Zamzow, Piet von Bubnoff, Nikolas Gieseler, Frank J Cancer Res Clin Oncol Original Article – Clinical Oncology PURPOSE: The expression of active tissue factor (TF) on the surface of microvesicles (MVs) is essential for the activation of the coagulation system and transduction of the signaling pathways in cancer cells. In its use as a biomarker for cancer-associated venous thromboembolism (VTE), TF has shown high expression variability. As a contribution to this discussion, we present a study investigating plasma samples from patients with various progressive tumors at high risk for VTE. METHODS: Based on our previous study uncovering microvesicles (MVs), the larger ectosome-like extracellular vesicles (EV), as the major source of TF activity in EV preparations, we now determined TF activity on enriched MVs isolated from plasma of cancer patients and compared it with that on MVs from healthy individuals. RESULTS: We found considerably higher amounts of MVs as well as higher levels of MV-bound TF activities in the plasma of cancer patients. We also show that preparations from plasma of cancer patients have the potency to induce ERK phosphorylation in a human tumor cell line through proteinase-activated receptor two (PAR2) activation. CONCLUSION: We suggest that MVs instead of whole EV preparations, and TF activity rather than its antigenic quantification should be used in clinical studies for identifying patients with progressive tumors at high risk for VTE. GRAPHIC ABSTRACT: [Image: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00432-019-03073-0) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-11-16 2020 /pmc/articles/PMC6985086/ /pubmed/31734835 http://dx.doi.org/10.1007/s00432-019-03073-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article – Clinical Oncology Ender, Fanny Freund, Annika Quecke, Tabea Steidel, Corinna Zamzow, Piet von Bubnoff, Nikolas Gieseler, Frank Tissue factor activity on microvesicles from cancer patients |
title | Tissue factor activity on microvesicles from cancer patients |
title_full | Tissue factor activity on microvesicles from cancer patients |
title_fullStr | Tissue factor activity on microvesicles from cancer patients |
title_full_unstemmed | Tissue factor activity on microvesicles from cancer patients |
title_short | Tissue factor activity on microvesicles from cancer patients |
title_sort | tissue factor activity on microvesicles from cancer patients |
topic | Original Article – Clinical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985086/ https://www.ncbi.nlm.nih.gov/pubmed/31734835 http://dx.doi.org/10.1007/s00432-019-03073-0 |
work_keys_str_mv | AT enderfanny tissuefactoractivityonmicrovesiclesfromcancerpatients AT freundannika tissuefactoractivityonmicrovesiclesfromcancerpatients AT quecketabea tissuefactoractivityonmicrovesiclesfromcancerpatients AT steidelcorinna tissuefactoractivityonmicrovesiclesfromcancerpatients AT zamzowpiet tissuefactoractivityonmicrovesiclesfromcancerpatients AT vonbubnoffnikolas tissuefactoractivityonmicrovesiclesfromcancerpatients AT gieselerfrank tissuefactoractivityonmicrovesiclesfromcancerpatients |